|Day Low/High||40.06 / 40.59|
|52 Wk Low/High||35.30 / 43.30|
AstraZeneca today announced positive overall survival (OS) results from the Phase III CASPIAN trial with IMFINZI in 1st-line extensive-stage small cell lung cancer (SCLC), a disease with significant unmet need and limited treatment options for patients.
AstraZeneca today announced detailed results from the interim analysis of the Phase III ASCEND trial at the European Hematology Association (EHA) Annual Congress in Amsterdam, showing CALQUENCE ® (acalabrutinib) significantly prolonged the time patients...
AstraZeneca today presented positive results from the Phase IIIb DIALIZE trial which investigated the efficacy and safety of LOKELMA (sodium zirconium cyclosilicate) for the treatment of hyperkalemia in patients with end-stage renal disease (ESRD) on...
A pre-specified exploratory analysis of renal data from the Phase III DECLARE-TIMI 58 trial, the broadest cardiovascular outcomes trial of a sodium-glucose co-transporter 2 (SGLT2) inhibitor, showed that FARXIGA (dapagliflozin) reduced the progression of...
AstraZeneca has presented three-year overall survival (OS) results from the Phase III PACIFIC trial of IMFINZI ® (durvalumab) in unresectable, Stage III non-small cell lung cancer (NSCLC) during the 2019 American Society of Clinical Oncology (ASCO) Annual...
AstraZeneca, in continued partnership with Bob Harper, a health and fitness expert, best-selling author and heart attack survivor, today announced the expansion of the Survivors Have Heart movement, taking its mission across the United States to unite...
A new integrated analysis of Phase III data for FASENRA ® (benralizumab) shows that patients with severe eosinophilic asthma who were continuously treated with the medicine for up to two years reduced their use of oral corticosteroids (OCS) and...
AstraZeneca will present new research across an industry-leading Oncology portfolio, including data for its transformational cancer medicines LYNPARZA ® (olaparib) and IMFINZI ® (durvalumab) at the 2019 American Society of Clinical Oncology (ASCO) Annual...
AstraZeneca is teaming up with PGA golf champion Jason Day to encourage newly diagnosed Stage IV non-small cell lung cancer patients to ask their doctor about biomarker testing (sometimes referred to as molecular testing or mutation testing), which can...
The oncology community gathered together last night to celebrate the winners of the first Cancer Community (C2) Awards.
AstraZeneca and Merck & Co., Inc.
Stocks closes up Friday after U.S. Treasury Secretary Steven Mnuchin says trade talks he held with China were 'constructive.'
AstraZeneca shares traded near the bottom of the London market Friday after the drugmaker agreed a potential $6.9 billion deal with Japan's Daiichi Sankyo Co. to develop and market a breast and gastric cancer treatment over the coming years.
Global stocks traded higher Friday, lifting U.S. equity markets towards their best opening quarter gain in a decade, as investors crept back into risk markets amid progress in U.S.-China trade talks, modestly higher fixed income yields and the opening trade of the biggest IPO since 2014.
Stock futures rise after Treasury Secretary Steven Mnuchin says trade talks between the U.S. and China have been 'constructive'; Lyft's IPO is priced at $72 a share, valuing the ride-hailing company at more than $24 billion; Tim Sloan steps down as CEO of Well Fargo.
Positive results from a pre-specified sub-analysis of the Phase III DECLARE-TIMI 58 trial showed that FARXIGA (dapagliflozin) reduced the relative risk of major adverse cardiovascular events (MACE) by 16% compared to placebo (15.
Data evaluating the cardiovascular (CV) effects of FARXIGA ® (dapagliflozin) , including hospitalization for heart failure (hHF) in adults with type 2 diabetes (T2D) have been selected for late-breaking clinical trial and oral presentations at the...
AstraZeneca today announced that the US Food and Drug Administration (FDA) has approved a label update for FARXIGA ® (dapagliflozin) and XIGDUO ® XR (dapagliflozin and metformin HCl extended-release) expanding use in patients with type 2 diabetes (T2D)...
The Phase III THEMIS trial met its primary endpoint which demonstrated that BRILINTA ® (ticagrelor) tablets, taken in conjunction with aspirin, showed a statistically-significant reduction in major adverse cardiovascular events (MACE, a composite of...
Guardant's liquid biopsy lets oncologists see all of the genomic information of a patient's tumor with a simple blood test. The alternative is a tissue biopsy which can be expensive and risky.
U.S. equity futures turned sharply red Thursday after data showed the weakest reading for December retail sales in nine years, erasing earlier gains linked to progress in trade talks between Washington and Beijing and data showing a surprise jump in January China export activity.
SAN DIEGO, Feb. 14, 2019 /PRNewswire/ -- Tanabe Research Laboratories U.
What trader has never both fallen in love with Nvidia, only to eventually feel the scorn of an angry lover's tortured vengeance?
Wall Street futures extended gains Thursday with investors using signals of moderate progress in trade talks between Washington and Beijing and data showing a surprise jump in January China export activity to boost the broadest measure of U.S. stocks to a 10% gain for the year.
AstraZeneca shares traded sharply higher Thursday after the U.K.-based drugmaker posted stronger-than-forecast fourth quarter earnings, and said 2019 revenues would continue to rise, thanks to increasing demand for its key cancer treatments.
These companies are working to plant their flag in a new landscape.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.